The Burrill Report


The Burrill Report (December 6, 2010): Industry, Consumers Have Differing Concerns Over FDA's User Fees (.MP3,12.59 Mb)

Members of the life sciences industry don’t think the user fees it pays regulators to review its products accelerate the process. At the same time, consumers think fees from industry should not be used to speed drug reviews and have waning trust for the U.S. Food and Drug Administration in the face of high profile product recalls, a new survey finds. The survey from the tax and advisory firm PwC and the San Diego-based regional trade group Biocom points to a disconnect between the industry, consumers and the FDA as renewal of the Prescription Drug User Fee Act, set to expire in 2012, moves to the top of the policy agenda for the industry. We spoke to Mike Mentesana, pharmaceutical research and development advisory services leader for PwC, about industry frustrations with the pace of drug approvals, the public’s eroding confidence in the agency, and the fight ahead over reauthorization of user fees charged to companies.

December 02, 2010
http://www.burrillreport.com/article-as_battle_readies_industry_public_question_user_fees.html